CATALYST DOSSIER · UPDATED 2026-11-06
$AHCO
biotech · convergence -22 · conviction AVOID
Price & Live Quote Loading live quote & chart…
Practice trade tools Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $AHCO?
Quantitative
Net Income (CY2026Q2) : $-133.9M (n/a YoY)
Catalysts
Multi-spoke convergence : 6 convergent signals fired: finra_short, sc13d, auto_macro_adp_payrolls, auto_macro_durable_goods, auto_macro_fx_rates
Risks
Position-sizing discipline : Conviction AVOID (-22 score) — size accordingly; no specific catalyst-fade risk flagged
Bear case
Squeeze unwind : Short interest can compress before retail catches the move — entry timing critical
Sympathy basket (cerebro)
NET via tech r=+0.93 sympathetic (score 2)
QBTS via tech r=+0.93 sympathetic (score -1)
NVDA via semis r=+0.83 sympathetic (score 12)
DIOD via semis r=+0.83 sympathetic (score 10)
AEI via real_estate r=+0.77 sympathetic (score -4)
MMI via real_estate r=+0.77 sympathetic (score -8)
Signals Firing
finra_short sc13d auto_macro_adp_payrolls auto_macro_durable_goods auto_macro_fx_rates auto_macro_yield_curve
Pick Track Record Date List Next-day max run Next-day close Hit +2%? 2026-11-03 sec_clean_value +19.2% +16.4% ✓ hit 2026-11-03 sec_top_gappers +19.2% +16.4% ✓ hit 2026-11-03 sec_top_moat_emerging +19.2% +16.4% ✓ hit 2026-09-08 sec_clean_gappers -3.2% -7.9% — 2026-09-08 sec_clean_value -3.2% -7.9% — 2026-09-08 sec_top_gappers -3.2% -7.9% — 2026-09-08 sec_top_moat_emerging -3.2% -7.9% —
Lifetime: 3/7 wins · hit-rate 42.9% on +2% intraday
Sympathy Basket NET via tech · score 2 QBTS via tech · score -1 NVDA via semis · score 12 DIOD via semis · score 10 AEI via real_estate · score -4 MMI via real_estate · score -8
Earnings Catalyst No recent earnings event.
Generate full earnings report
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks
and its losses — see the
trust report and
methodology .
Not financial advice. Confirm independently before trading.